Mechanisms of Parasite Dissemination in Visceral Leishmaniasis

内脏利什曼病寄生虫传播机制

基本信息

  • 批准号:
    10062846
  • 负责人:
  • 金额:
    $ 54.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-12-01 至 2022-11-30
  • 项目状态:
    已结题

项目摘要

Visceral leishmaniasis (VL), caused by the intracellular protozoan Leishmania donovani or L. infantum, is one of the “Neglected Tropical Diseases” that impacts the poor of the world. People are infected when the parasite is deposited in the dermis during the bloodmeal of the sand fly vector. The majority of people who are infected develop a latent infection without clinical disease. However, some individuals develop a chronic progressive infection characterized by fever, cachexia, massive splenomegaly, pancytopenia and ultimately death. The mechanism of parasite dissemination from the skin and the reason that only a minority of infected individuals develop full-blown disease are not understood, but malnutrition has been identified as a major risk factor for the development of active disease. Progress in understanding the pathogenesis of VL has been hindered by the lack of models suitable for study of parasite dissemination from the site of skin inoculation. The research proposed here will use a clinically relevant animal host (malnourished mice) and natural parasite transmission by the bite of an infected sand fly to define the mechanisms of parasite dissemination that lead to VL. Our central hypothesis is that parasite dissemination is driven by altered cutaneous inflammation and myeloid cell-mediated trafficking of the parasite from the skin to visceral organs. Our published and preliminary data suggest a three- component model of parasite dissemination that involves (1) increased influx of inflammatory cells to the site of parasite entry in the skin; (2) hyper-migration of infected myeloid cells (primarily monocytes and neutrophils) from the skin, and (3) increased escape of migrating infected myeloid cells from the draining lymph node. We propose that co-existent malnutrition- and vector-related inflammation, as would occur in endemic regions of the world, will synergistically promote parasite dissemination and active VL. In Specific Aim 1 we will determine the dynamics of early myeloid cell recruitment and parasite fate in the skin following infection by needle injection and vector-transmission. Our working hypothesis is that dysregulated cutaneous inflammation, in response to malnutrition or sand fly feeding, drives the altered dynamics of myeloid cell trafficking and pathogen capture in the skin. In particular, we will determine how the dysregulated inflammation leads to differences in neutrophil and inflammatory monocyte influx, parasite capture, and cell egress from the skin. In Specific Aim 2 we will determine the mechanisms of myeloid cell trafficking and L. donovani dissemination from the skin to visceral organs following needle injection and vector-transmission. Our working hypothesis is that increased myeloid cell trafficking through the afferent lymphatic, coupled with reduced cell retention in the draining LN, leads to parasite dissemination. Changes in inflammatory mediators and chemokines and their receptors are likely to underpin parasite trafficking to the visceral organs. Understanding the mechanisms behind parasite visceralization can lead to interventions to reduce the risk for parasite dissemination and development of this devastating disease.
内脏利什曼病是由细胞内原生动物杜氏利什曼原虫或婴儿利什曼原虫引起的 影响世界穷人的“被忽视的热带病”。当寄生虫被感染时,人就会被感染 在沙蝇媒介的血餐过程中沉积在真皮中。大多数被感染的人 发展为潜伏感染,而不是临床疾病。然而,一些人会患上慢性进行性疾病 感染的特征是发烧、恶病质、大量脾肿大、全血细胞减少并最终死亡。这个 寄生虫经皮肤传播的机制及仅有少数感染者的原因 发生全面疾病的原因尚不清楚,但营养不良已被确定为 活动性疾病的发展。VL发病机制的研究进展受阻于 缺乏适合研究寄生虫从皮肤接种部位传播的模型。这项研究 这里提出将使用临床相关的动物宿主(营养不良的小鼠)和自然寄生虫传播 通过被感染的沙蝇的叮咬来确定导致VL的寄生虫传播机制。我们的中央 假设寄生虫的传播是由改变的皮肤炎症和髓系细胞介导的 将寄生虫从皮肤传播到内脏器官。我们公布的和初步的数据表明,有三个- 寄生虫传播的组成部分模型,涉及(1)炎性细胞增加流入 寄生虫进入皮肤;(2)受感染的髓系细胞(主要是单核细胞和中性粒细胞)的过度迁移 从皮肤,以及(3)迁移感染的髓系细胞从引流淋巴中逃逸的增加。我们 建议营养不良和病媒相关炎症共存,就像在美国流行地区一样 它将协同促进寄生虫的传播和活跃的VL。在具体目标1中,我们将确定 针刺感染皮肤后早期髓系细胞募集和寄生虫归宿的动态变化 媒介传播。我们的工作假设是,失调的皮肤炎,对 营养不良或沙蝇喂养,推动了髓系细胞运输和病原体捕获的改变 皮肤。特别是,我们将确定炎症调节失调如何导致中性粒细胞的差异。 以及炎性单核细胞流入、寄生虫捕获和细胞从皮肤流出。在具体目标2中,我们将 确定髓系细胞转运和杜氏杆菌从皮肤到内脏传播的机制 针头注射和媒介传播后的器官。我们的工作假说是髓系细胞增多 通过传入淋巴管的运输,加上引流层中细胞滞留的减少,导致寄生虫 传播。炎症介质和趋化因子及其受体的变化可能是 寄生虫传播到内脏器官。了解寄生虫内脏作用背后的机制可以 采取干预措施,减少寄生虫传播和发展这一毁灭性疾病的风险。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter C. Melby其他文献

<em>In situ</em> cytokines (IL-4, IL-10, IL-12, IFN-γ) and chemokines (MCP-1, MIP-1α) gene expression in human <em>Leishmania</em> (<em>Leishmania</em>) <em>mexicana</em> infection
  • DOI:
    10.1016/j.cyto.2014.05.016
  • 发表时间:
    2014-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Guillermo Valencia-Pacheco;Elsy Nalleli Loría-Cervera;Erika Ivett Sosa-Bibiano;Elsy B. Canché-Pool;Alberto Vargas-Gonzalez;Peter C. Melby;Fernando J. Andrade-Narvaez
  • 通讯作者:
    Fernando J. Andrade-Narvaez
Concentration of Pentostam in human breast milk.
人母乳中 Pentostam 的浓度。
Malnutrition exacerbates pathogenesis of Lutzomyia longipalpis sand fly-transmitted Leishmania donovani
营养不良加剧了长喙长翅沙蝇传播的杜氏利什曼原虫的发病机制
  • DOI:
    10.1038/s42003-025-08106-8
  • 发表时间:
    2025-05-13
  • 期刊:
  • 影响因子:
    5.100
  • 作者:
    Eva Iniguez;Johannes Doehl;Pedro Cecilio;Tiago Donatelli Serafim;Caroline Percopo;Yvonne Rangel-Gonzalez;Somaditya Dey;Elvia J. Osorio;Patrick Huffcutt;Sofia Roitman;Claudio Meneses;Mara Short;Jesus G. Valenzuela;Peter C. Melby;Shaden Kamhawi
  • 通讯作者:
    Shaden Kamhawi
Vaccination Against Cutaneous Leishmaniasis

Peter C. Melby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter C. Melby', 18)}}的其他基金

Physician-Scientist Training in Emerging Infectious Diseases
新发传染病的医师科学家培训
  • 批准号:
    10647762
  • 财政年份:
    2021
  • 资助金额:
    $ 54.82万
  • 项目类别:
Physician-Scientist Training in Emerging Infectious Diseases
新发传染病的医师科学家培训
  • 批准号:
    10270872
  • 财政年份:
    2021
  • 资助金额:
    $ 54.82万
  • 项目类别:
Mechanisms of Parasite Dissemination in Visceral Leishmaniasis
内脏利什曼病寄生虫传播机制
  • 批准号:
    10302274
  • 财政年份:
    2017
  • 资助金额:
    $ 54.82万
  • 项目类别:
Malnutrition-related Lymph Node Dysfunction and Risk of Visceral Leishmaniasis
营养不良相关的淋巴结功能障碍和内脏利什曼病的风险
  • 批准号:
    8702843
  • 财政年份:
    2014
  • 资助金额:
    $ 54.82万
  • 项目类别:
Discovery of 4-aminoquinoline therapeutics for visceral leishmaniasis
发现内脏利什曼病的 4-氨基喹啉疗法
  • 批准号:
    8207443
  • 财政年份:
    2010
  • 资助金额:
    $ 54.82万
  • 项目类别:
NOS2 and arginase in visceral leishmaniasis-FIRCA supplement
内脏利什曼病中的 NOS2 和精氨酸酶 - FIRCA 补充剂
  • 批准号:
    7758284
  • 财政年份:
    2009
  • 资助金额:
    $ 54.82万
  • 项目类别:
NOS2 and arginase in visceral leishmaniasis-FIRCA supplement
内脏利什曼病中的 NOS2 和精氨酸酶 - FIRCA 补充剂
  • 批准号:
    7559198
  • 财政年份:
    2009
  • 资助金额:
    $ 54.82万
  • 项目类别:
NOS2 and arginase in visceral leishmaniasis-FIRCA supplement
内脏利什曼病中的 NOS2 和精氨酸酶 - FIRCA 补充剂
  • 批准号:
    8012292
  • 财政年份:
    2009
  • 资助金额:
    $ 54.82万
  • 项目类别:
NOS2 and arginase in visceral leishmaniasis
内脏利什曼病中的 NOS2 和精氨酸酶
  • 批准号:
    7347521
  • 财政年份:
    2005
  • 资助金额:
    $ 54.82万
  • 项目类别:
NOS2 and arginase in visceral leishmaniasis
内脏利什曼病中的 NOS2 和精氨酸酶
  • 批准号:
    7009285
  • 财政年份:
    2005
  • 资助金额:
    $ 54.82万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 54.82万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 54.82万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 54.82万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 54.82万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 54.82万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 54.82万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 54.82万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 54.82万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 54.82万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 54.82万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了